Brought to you by 
Aestus licenses rights to Astellas' FK614 for pain
13 Jul 2010
Executive Summary
Aestus Therapeutics Inc. (neurological diseases) has licensed exclusive global rights to Astellas Pharma Inc.'s FK614 (renamed ATx08001), a diabetes drug candidate that Aestus found has implication in pain, including post-herpetic neuralgia (PHN).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aestus licenses rights to Astellas' FK614 for pain
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice